$78.67
0.740.95%
Last update: Nov 11, 7:13 AM
BridgeBio Pharma Inc
BBIONASDAQ
BridgeBio Pharma rose 18.2% from $66.58 to $78.67, ahead of the S&P 500's +9.8%. Its worst day was Feb 5 (−15.2%), and its low came Oct 13 at $63.30.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
BridgeBio Pharma shares fell 15.2%, while the S&P 500 fell 1.2%.
−15.2%, the year's worst day · S&P 500 −1.2%
EPS of $-1.00 missed the $-0.67 estimate on $154.2M revenue (est. $149.5M).
Story events cover the past 12 months · Times ET
−2.6% · S&P 500 +0.8%
BridgeBio Pharma shares rose 13.2%, while the S&P 500 fell 0.2%.
+13.2% · S&P 500 −0.2%
BridgeBio Pharma shares rose 7.1%, while the S&P 500 rose 2.9%.
+7.1% · S&P 500 +2.9%
EPS of $-0.84 missed the $-0.63 estimate on $194.5M revenue (est. $178.8M).
−0.1% · S&P 500 +0.8%
BridgeBio Pharma closed at its highest level of the year, 35.4% above where the year started.
+15.1%, the year's best day · S&P 500 +0.8%
EPS of $-0.78 missed the $-0.59 estimate on $243.7M revenue (est. $220.3M).
−1.1% · S&P 500 −0.3%
BridgeBio Pharma closed at its lowest level of the year, 4.9% below where the year started.
−3.7% · S&P 500 0.0%
EPS of $-0.42 beat the $-0.57 estimate on $353.2M revenue (est. $295.9M).
+6.0% · S&P 500 −1.8%
Where it ended: a close of $78.67 on Nov 10, 2026. Up next: Q4 2026 earnings on Feb 23, 2027 (EPS est. $-0.52, revenue est. $308.6M).
Nothing in the past 12 months.
All BBIO dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BBIO and SPY from Benzinga historical bars. Not investment advice.
